
A weekly injection built for weight loss just proved it can also stop heart attacks and strokes in people who already have heart disease.
Quick Take
- The SELECT trial found semaglutide cut heart attacks, strokes, and cardiovascular deaths in overweight adults with existing heart disease but no diabetes.
- The Food and Drug Administration used that trial to approve a new heart-protection label for Wegovy.
- A separate trial called SUMMIT showed tirzepatide helped patients with obesity and a tough type of heart failure feel and move better.
- Both drugs’ proven benefits apply to specific patients, not everyone with obesity or heart disease.
- Cost and insurance coverage still limit who can actually get and stay on these medicines.
What the SELECT Trial Actually Showed
Researchers enrolled 17,604 overweight or obese adults who already had heart disease but did not have diabetes. Half got weekly semaglutide, the drug sold as Wegovy. Half got a placebo. After nearly four years, people on semaglutide had fewer heart attacks, strokes, and cardiovascular deaths than those on the dummy shot. This was the first weight-loss drug ever shown to cut those major heart problems in a large, controlled study.
Novo Nordisk, the company that makes semaglutide, reported a 20% relative reduction in combined heart attacks, strokes, and cardiovascular deaths compared to placebo. The Food and Drug Administration reviewed the full trial data and agreed it was strong enough to matter. Wegovy’s label now includes a cardiovascular-risk-reduction claim, something no obesity drug had carried before.
A Second Drug Targets a Different Kind of Heart Failure
Tirzepatide, sold as Zepbound, was tested in a trial called SUMMIT on patients with obesity and a form of heart failure where the heart muscle stays stiff instead of weak. Only 9.9% of tirzepatide patients reached the trial’s main problem point, compared to 15.3% on placebo. That gap came mostly from fewer hospital visits for worsening heart failure, not from stopping deaths outright.
Patients on tirzepatide also walked farther in six minutes, scored better on heart-failure symptom surveys, and lost roughly 11% to 12% more weight than those on placebo. For people living with breathlessness and swelling from heart failure, those day-to-day improvements carry real weight, even when the trial wasn’t built to prove a drop in cardiovascular deaths specifically.
Why Doctors Are Calling This a New Era
Cardiologists have spent decades treating obesity as a risk factor to manage around, leaning on statins, blood pressure pills, and lifestyle advice. These two trials mark something different: a drug originally built for weight loss now has trial-proven heart benefits of its own. That shift explains why Mayo Clinic specialists and heart groups are framing this as a genuine change in cardiovascular care, not just another diet drug headline.
Still, the proof is specific. SELECT studied people who already had heart disease. SUMMIT studied a narrow type of heart failure. Neither trial tells us these drugs prevent heart disease in someone who has never had it, and neither proves the benefit works the same way across every incretin drug on the market, including lower-dose versions or pills.
What Americans Still Can’t Easily Get
The clinical results mean little if patients cannot afford or keep taking the drugs. A nationwide claims study found only 46.3% of obese patients without diabetes were still on a GLP-1 drug after 180 days, and that number kept dropping over the following year. More recent data show adherence improving, but still far from universal, with just over 61% of new patients sticking with treatment at three months.
Insurance is a big reason why. A 2026 industry survey found the share of employers covering these drugs for obesity fell from 72% to 60% in a single year as pharmacy costs climbed. Separate research found coverage without extra paperwork was rare, available to less than 4% of patients checked, while over a quarter of coverage requests came back undetermined. Good medicine does not help much if the paperwork says no.
None of this erases what SELECT and SUMMIT proved. For the right patients, a drug once known mainly for shrinking waistlines is now shown to protect against heart attacks, strokes, and the misery of worsening heart failure. The next test for American medicine isn’t whether these drugs work. It’s whether ordinary patients and their insurance plans can actually afford to use them.
Sources:
youtube.com, nejm.org, acc.org, novonordisk-us.com, healio.com, nber.org, link.springer.com, cvshealth.com













